A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

About the trial

Sponsor

ModernaTX, Inc.

Tested

Influenza Vaccine 1 (biological), mRNA-1083.1 (biological), mRNA-1083.2 (biological), mRNA-1083.3 (biological), Investigational Influenza Vaccine 1 (biological), Investigational COVID-19 Vaccine 1 (biological), COVID-19 Vaccine 1 (biological), Investigational Influenza Vaccine 2 (biological), Influenza Vaccine 2 (biological), mRNA-1083 (biological), Investigational COVID-19 Vaccine 2 (biological), COVID-19 Vaccine 2 (biological)

Dates

Started 2023-04-14; completion 2024-12-03

Results posted

Yes

The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine composition and dose level to evaluate in a subsequent Phase 3 clinical trial in adults. The purpose of Part 2 of this study is to generate safety and immunogenicity data for additional mRNA-1083 compositions and dose levels in young adults ≥18 years and \<50 years of age.

From ClinicalTrials.gov, last updated 2025-12-23. Full record, eligibility and contacts (opens in a new tab)

Industry funding

ModernaTX, Inc. reported $650,072 in research payments for this study in 2025 (136 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.